Decreasing Incidence of Gastric Cancer and *H. pylori* Infection a 10-Year Study from an Asian Population

Jose D Sollano¹, Karen Estelle C de Lunas¹ and Francesco Marotta**

¹University of Santo Tomas, Manila, Philippines
²ReGenera Research Group for Aging Intervention and Montenapoleone Medical Center, Milano, Italy

Worldwide, cancer of the stomach is the fourth most common cancer and is the second leading cause of cancer deaths. Gastric cancer is common in many regions of Asia and one of the many factors associated with it is the high prevalence of *Helicobacter pylori* (*Hp*) infection. *Hp* has been designated by the WHO as a class 1 (definite) carcinogen and the association between chronic *Hp* infection and the development of gastric cancer has been established by numerous publications. Up to 76-95% of gastric cancers are associated with *Hp* infection [1-3]. Among the many factors expressed by *Hp*, gastric carcinogenesis via the cag A pathway is the most studied. In individuals infected with CagA-positive strains, a meta-analysis of 16 case-control studies showed a further increase in the risk for gastric cancer by 1.64 fold [4] However, due to improved sanitation amidst better living conditions, heightened patients and physician awareness and widespread *Hp* eradication practices, a decreasing prevalence of *Hp* infection is observed even in previous high-prevalence regions. We have also noted that the number of patients with gastric cancer consulting our institution, a tertiary academic hospital, has diminished remarkably in the last several decades. Thus, we designed a study to determine the incidence of gastric cancer, as well as, *Hp* infection over a ten-year period as seen in our tertiary referral center and evaluated the relationship between *Hp* infection and gastric cancer.

In order to determine current *Hp* infection, we performed rapid urease tests (RUT) and/or histopathology of gastric biopsies taken from the antrum, incisura angularis and gastric corpus on all adult patients who underwent esophageagastroduodenoscopy (EGD) between January 1, 2004 until December 31, 2013. In addition to *Hp* status, other demographic data were also recorded, i.e., age, sex, height, weight, and BMI. Over a 10-year period, a total of 8,520 patients were included in this analysis. Ninety-six (1.13%) patients were diagnosed with gastric adenocarcinoma (9.6 ± 6.4 cases/year) and 1,708 (20.1%) patients tested positive for *Hp* infection (170.9 ± 79.0 cases/year). Up to 82% are non-cardia gastric cancers and 42% are infected with *Hp* (Table 1). The most common clinical presentation of gastric cancer is epigastric pain (30%). Half of the lesions are infiltrating and 11% are completely obstructing lesions at the time of diagnosis. The Chi square test was used to determine whether *Hp* infection was significantly associated with gastric malignancy while the Pearson correlation test was used to establish a relationship between the annual incidence of gastric cancer and that of *Hp* infection.

Our analysis revealed that *Hp* infection is significantly associated with gastric malignancy (p<0.001) among the patients we examined during the last 10 years. In addition, a strong correlation was determined between the decreasing trend in the annual incidence of *Hp* infection (31.71% to 8.69%) and the corresponding decrease in the incidence of gastric malignancy (1.82% to 0.21%) observed from 2004 to 2013 (R=0.884, p=0.001; Figure 1).

In 2006, a review of 5 meta-analyses showed that *H pylori* infection is associated with a two-fold increase in the risk of gastric cancer [5,6]. A meta-analysis of 15 papers, 10 of which were from Japan, revealed that *H. pylori* eradication therapy statistically diminished the prevalence of clinical gastric cancer by approximately one third [7]. Studies by Uemura et al showed that recurrence of early gastric cancer can be prevented by *Hp* eradication [8]. In the West reports of a diminishing incidence of gastric cancer related to a decrease in *Hp* prevalence have been published several decades ago [9].

Experts believe that a recent report of the global decrease in gastric cancer incidence is largely attributed to *Hp* eradication. This is probably true in the in the areas of the world where most patients have easy access to medical care and *Hp* eradication is aggressively pursued by both primary care physicians and by national health services.

The result of this study describes the real world observations on how the incidence of gastric cancer is significantly influenced by the diminishing number of *Hp*-infected patients in the developing world -where *Hp* infection used to be prevalent. In Asia, access to care, as well as, health services is generally poor, yet a phenomenon similar to what is observed in the West is slowly unfolding currently [10,11].

Among other factors, increasing awareness of both the public and medical colleagues about the risks of gastric cancer associated with *Hp* infection and timely and aggressive *Hp* eradication treatment of infections diagnosed during opportunistic *Hp* testing in the primary physicians’ clinics may be additional factors contributing to these observations. In 2005, we also reported a significant reduction in peptic ulcer disease and *Hp* prevalence in our center over a seven-year period [12,13]. These time-trend observations in gastric malignancy and *Hp* are similar with those noted with peptic ulcer disease whereby a strong correlation with the decreasing trend in the annual incidence of *Hp* infection was determined earlier.

Major clinical practice guidelines recommend strongly the testing for and subsequent eradication of *Hp* infection among those who have tested positive for the infection, most notably in regions where the *Hp* prevalence is high, in those with severe gastric atrophy, prior history of resected gastric cancer, those who have had a history (and complications) of peptic ulcer disease, etc. The Maastricht IV recommends to eradicate *Hp* infection because it is the most consistent risk factor for gastric cancer. *Hp* eradication abolishes the inflammatory response and slows, arrests and in some cases reverses the progression of atrophy. Its elimination is therefore the most promising strategy to reduce the incidence of gastric cancer because there is strong evidence...

Showcasing recent research output in a timely and updated manner.

Indexing at PubMed (partial), Scopus, EBSCO, Index Copernicus, Google Scholar etc.

Special issues on the current trends of scientific research.


P value

Quality and quick editorial, review and publication processing.

Authors, Reviewers and Editors rewarded with online Scientific Credits.

599, 000 Open Access Journals.

Sharing Option: Social Networking Enabled.

OMICS International: Publication Benefits & Features

Unique features:

• Increased global visibility of articles through worldwide distribution and indexing
• Showcasing recent research output in a timely and updated manner
• Special issues on the current trends of scientific research

Special features:

• 700 Open Access Journals
• 50,000 Editorial team
• Rapid review process
• Quality and quick editorial, review and publication processing
• Indexing at PubMed (partial), Scopus, BS&CO, Index Copernicus, Google Scholar etc.
• Sharing Options: Social Networking Enabled
• Authors, Reviewers and Editors rewarded with online Scientific Credits
• Better discount for your subsequent articles

Submit your manuscript at: http://www.omicsgroup.org/journals/submission


Table 1: Distribution of patients according to gastric cancer and H. pylori Status.

<table>
<thead>
<tr>
<th>Gastric cancer</th>
<th>Hp positive</th>
<th>Hp negative</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>No gastric cancer</td>
<td>1873</td>
<td>6752</td>
<td>0.001</td>
</tr>
</tbody>
</table>

Table 1: Distribution of patients according to gastric cancer and Hp Status.

that its eradication reduces the risk of gastric cancer development.

While, as shown above, an effective eradication treatment has always to be pursued, an issue of growing concern is not only the rising incidence of adverse effects by administering high dosage of antibiotics (up to about 30%), but also the antibiotic resistance. This is significantly affecting the success of triple therapies eradication rates. In particular, between 38% and over 50% of eradication treatment with either metronidazole or clarithromycin, respectively, have been reported [14]. Despite several reports suggesting the potential use of herbal compounds either in adjunct [15] or as a sole treatment [16] for eradication of HP, to date no firm conclusion can be drawn due to the wide heterogeneity and often poor design of such studies [17]. Ourselves, few years ago, did stool culture of HP, tested it in vitro against multiple potential herbal extracts and administered subjects with such would-be “specific” formulations shown to be the most bactericidal (Marotta et al. unpublished). Although our population consisted of naïve subjects but also a group which had failed the first eradication attempt with conventional regimes, the eradication rate in both was poor (below 45%) and the study had to be abandoned for ethical implications.

While the search of any either pharmacological or phytopharmacological optimization of eradication treatments moves on, for the time being, a strict application of the above guidelines deserves the highest attention from medical practitioners.

References


Figure 1: Correlation of gastric cancer and H. pylori Incidence from 2004-2013.